These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

108 related items for PubMed ID: 1394824

  • 21. Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer.
    Igawa M, Ohkuchi T, Ueki T, Ueda M, Okada K, Usui T.
    J Urol; 1990 Sep; 144(3):662-5. PubMed ID: 2388322
    [Abstract] [Full Text] [Related]

  • 22. [Clinical study of modified M-VAC therapy with one 21-day cycle for advanced urothelial cancer].
    Nakanishi S, Matsuzaki M, Morikawa H, Nakano M, Komatsu H.
    Hinyokika Kiyo; 2004 Oct; 50(10):667-71. PubMed ID: 15575216
    [Abstract] [Full Text] [Related]

  • 23. Chemotherapy of urothelial tract tumors.
    Yagoda A.
    Cancer; 1987 Aug 01; 60(3 Suppl):574-85. PubMed ID: 3297286
    [Abstract] [Full Text] [Related]

  • 24. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
    Saxman SB, Propert KJ, Einhorn LH, Crawford ED, Tannock I, Raghavan D, Loehrer PJ, Trump D.
    J Clin Oncol; 1997 Jul 01; 15(7):2564-9. PubMed ID: 9215826
    [Abstract] [Full Text] [Related]

  • 25. [Combination chemotherapy with M-VAC protocol in metastatic urothelial cancer].
    Sella A, Flex D, Gafni D, Rabinovitz O, Sulkes A, Baniel J.
    Harefuah; 1999 Feb 15; 136(4):268-71, 340, 339. PubMed ID: 10914214
    [Abstract] [Full Text] [Related]

  • 26. [Outcome of treatment with surgical resection of the remaining tumor after modified M-VAC treatment for advanced urothelial carcinoma].
    Narita S, Nakano M, Matsuzaki M, Watanabe J, Morikawa H, Murata H, Oda H, Komatsu H.
    Hinyokika Kiyo; 2005 Mar 15; 51(3):155-8. PubMed ID: 15852667
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
    Scher HI.
    J Urol; 1992 Nov 15; 148(5):1625-6. PubMed ID: 1433578
    [No Abstract] [Full Text] [Related]

  • 29. [M-VAC chemotherapy for advanced urothelial cancer--side effects and their management].
    Noguchi S, Kubota Y, Shuin T, Masuda M, Misaki H, Yao M, Kondoh K, Sakuramoto T, Hosaka M.
    Hinyokika Kiyo; 1994 Aug 15; 40(8):677-82. PubMed ID: 7942364
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) for advanced TCC of urothelium.
    Huang CH, Hsieh HH, Wang JM, Hsu K, Yang WC, Yu TJ.
    J Formos Med Assoc; 1992 Jul 15; 91(7):699-703. PubMed ID: 1360298
    [Abstract] [Full Text] [Related]

  • 32. Analyses of factors affecting the outcome of combination chemotherapy in patients with advanced bladder cancer.
    Igawa M, Ohkuchi T, Ueda M, Usui T, Kawanishi M.
    Eur Urol; 1991 Jul 15; 20(1):12-5. PubMed ID: 1743224
    [Abstract] [Full Text] [Related]

  • 33. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer.
    Siefker-Radtke AO, Millikan RE, Tu SM, Moore DF, Smith TL, Williams D, Logothetis CJ.
    J Clin Oncol; 2002 Mar 01; 20(5):1361-7. PubMed ID: 11870180
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. [Clinical and pathological evaluations of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) chemotherapy for advanced urothelial cancers].
    Takenaka A, Gotoh A, Hara I, Gohji K, Ogawa T, Arakawa S, Matsumoto O, Kamidono S, Hamami G, Itani A.
    Gan To Kagaku Ryoho; 1990 Sep 01; 17(9):1909-15. PubMed ID: 2393308
    [Abstract] [Full Text] [Related]

  • 36. Transitional cell carcinomatous meningitis after M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) chemotherapy.
    Bishop JR, Moul JW, Maldonado L, McLeod DG.
    Urology; 1990 Oct 01; 36(4):373-7. PubMed ID: 2219624
    [Abstract] [Full Text] [Related]

  • 37. Primary transitional cell carcinoma of prostate: case with lymph node metastasis eradicated by neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) therapy.
    Takashi M, Sakata T, Nagai T, Kato T, Sahashi M, Koshikawa T, Miyake K.
    Urology; 1990 Jul 01; 36(1):96-8. PubMed ID: 2368239
    [Abstract] [Full Text] [Related]

  • 38. M-VECA (methotrexate, vinblastine, epidoxorubicin and carboplatin) in the treatment of advanced urothelial carcinoma.
    Lorusso V, Berardi F, Brandi M, Mastria A, Paradiso A, Catino AM, Tatulli C, De Lena M.
    Tumori; 1993 Jun 30; 79(3):191-4. PubMed ID: 8236502
    [Abstract] [Full Text] [Related]

  • 39. [Results of modified M-VAC chemotherapy for advanced urothelial carcinoma].
    Miura N, Numata K, Azuma K, Hashine K, Sumiyoshi Y.
    Nihon Hinyokika Gakkai Zasshi; 2007 May 30; 98(4):589-94. PubMed ID: 17564101
    [Abstract] [Full Text] [Related]

  • 40. Current status of systemic chemotherapy for octogenarians with advanced urothelial cancer in Japan: a Japanese multi-institutional study (CURE study).
    Matsui Y, Ogawa O, Ishitsuka R, Miyazaki J, Inoue T, Kageyama S, Sugimoto M, Mitsuzuka K, Shiraishi Y, Kinoshita H, Wakeda H, Nomoto T, Kikuchi E, Fujie K, Keino N, Nishiyama H.
    Int J Clin Oncol; 2016 Dec 30; 21(6):1142-1149. PubMed ID: 27349431
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.